iBio, Inc. Stock: price and insider trades · United States

iBio, Inc. belongs to the Health Care sector. Filings by its managers are published through SEC (Form 4). In the past year (18 October 2025 to 18 October 2026), 3 filings came from 3 insiders.

Every open-market trade in the period is a purchase: 3 purchases worth €83k, from 3 insiders, and not a single sale. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Duran Felipe filed the largest purchase, €44k, on 23 March 2026. Those buying include 1 finance chief and 1 senior executive.

Within a 30-day window, 3 purchases overlapped with buying by a second insider. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. The clock since the last published purchase (27 March 2026) now reads 205 days. Filings reach the SEC (Form 4) feed a median of 4 days after the trade. US insiders must file a Form 4 within two business days of a trade.

Across the 5,814 companies tracked on its exchange, the median is 19 filings; at 3 filings, this issuer sits below that mark. The full history, which starts in 2016, counts 11 purchases against 13 sales.

Elsewhere in the same sector, our signals recently picked up insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.